Sep
16
2021
On demand

AAV manufacturing with stable producer cells for industrial scale vector production

As gene therapy moves towards more frequent indications with large patient cohorts or systemic administration, incomparably higher amounts of vector material are required. Stable helper virus-free AAV producer cell lines are the technology of choice to elevate the manufacturing scale of AAV gene therapy vectors to this next level. 

The stable ELEVECTA® producer platform offers an “easy-to-scale” production platform in which AAV production is simply started via induction as all components necessary for AAV production are stably integrated in the cells. The platform makes AAV production as simple as monoclonal antibody production.

  • Eliminate any transient transfection/helper virus infection step from your AAV production process
  • Achieve reliable AAV production by simple induction of suspension producer cells
  • Easy scale-up of AAV production instirred tank bioreactors
  • Increase AAV production in stirred tank bioreactor up to E15 vg/L using an intensified process
  • Free choice of stable producer cell line based on HEK 293 or CAP® cells.

Ben Hudjetz, PhD

Senior Scientist, Cell Line Development, CEVEC Pharmaceuticals GmbH

Ben Hudjetz is a Senior Scientist in the Cell Line Development Department at CEVEC. He holds a PhD in Cell Biology and Virology from the Heinrich-Pette-Institute (University of Hamburg). Before joining CEVEC in 2017 he worked on the development of nucleic acid-based drugs. In his current position his main scientific focus is the development and optimization of CEVEC’s ELEVECTA stable AAV producer cell lines based on HEK293 cells.

SPEAKERS

Ben Hudjetz, PhD
Senior Scientist, Cell Line Development, CEVEC Pharmaceuticals GmbH

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
9
Hrs
11
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
29
Days
17
Hrs
11
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
21
Days
9
Hrs
11
Min
Register

Optimizing E. Coli cell growth performance with in-line, real-time OD600...

T Buch
R Shanbaky
Tanja Buch
Tanja Buch
Technical Director at Biifactory Competence Center
Ramsey  Shanbaky
Ramsey Shanbaky
Bioprocess Applications Manger at C Technologies, Inc - a Repligen Company
1 Jun 2022
14
Days
17
Hrs
11
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
9
Hrs
11
Min
Register